Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | HTR6 | P50406 | 3/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760663 | 1.00 | CYP1A2 (0.64) | CYP1A2ADRA2AALDH1A1CHRM1DRD2 | |
| Hydrochloric Acid SCHEMBL30330842 | 0.98 | CYP1A2 (0.62) | CYP1A2ADRA2AALDH1A1CHRM1DRD2 | |
| Fluoride SCHEMBL30212759 | 0.98 | CYP1A2 (0.62) | CYP1A2ADRA2AALDH1A1CHRM1DRD2 | |
| Cyanide SCHEMBL30330259 | 0.94 | CYP1A2 (0.58) | CYP1A2ADRA2AALDH1A1CHRM1DRD2 | |
| SCHEMBL11921 | 0.93 | — | — | |
| SCHEMBL60463 | 0.93 | — | — | |
| SCHEMBL11926 | 0.93 | — | — | |
| SCHEMBL27836717 | 0.92 | CYP1A2 (0.56) | CYP1A2ADRA2AALDH1A1CHRM1DRD2 | |
| Iodide SCHEMBL29010172 | 0.91 | CYP1A2 (0.53) | CYP1A2ADRA2AALDH1A1S1PR1S1PR3 | |
| Bromide SCHEMBL27865865 | 0.91 | CYP1A2 (0.53) | CYP1A2ADRA2AALDH1A1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001877-A1 | METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT | Bioniqs Limited (GB) | 2008-12-17 | — | — | EP | claimed |
| WO-2007110637-A1 | METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT | BIONIQS LIMITED (GB) | 2007-10-04 | — | — | WO | claimed |
| US-12569679-B2 | Treatment delivery system | WearOptimo Pty Ltd (AU) | 2026-03-10 | — | — | US | disclosed |
| US-12484814-B2 | Actuator system | WearOptimo Pty Ltd (AU) | 2025-12-02 | — | — | US | disclosed |
| US-20250025078-A1 | ELECTRODE ARRANGEMENT | WearOptimo Pty Ltd (AU) | 2025-01-23 | — | — | US | disclosed |
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20230053962-A1 | ANALYTE MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2023-02-23 | — | — | US | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220346679-A1 | ANALYTE MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2022-11-03 | — | — | US | disclosed |
| EP-4037552-A1 | ANALYTE MEASUREMENT SYSTEM | Wearoptimo Pty Ltd (AU) | 2022-08-10 | — | — | EP | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| WO-2018022668-A2 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022664-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022666-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| CN-107156194-A | Environment-friendly high-efficiency citrus insecticide | 嘉禾天奉富硒果业有限公司 | 2017-09-15 | — | — | CN | disclosed |
| US-20150362482-A1 | METHODS OF DETECTING NEUROTOXIN USING SYNAPTIC ACTIVITY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-12-17 | — | — | US | disclosed |
| US-20150153325-A1 | TOXIN DETECTION USING STEM CELL DERIVED NEURONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-06-04 | — | — | US | disclosed |
| WO-2014138663-A1 | METHODS OF DETECTING NEUROTOXIN USING SYNAPTIC ACTIVITY | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY, on behalf of (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2013170206-A1 | TOXIN DETECTION USING STEM CELL DERIVED NEURONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF U.S. ARMY RESEARCH & MATERIAL COMMAND (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2010131058-A1 | PRODUCT FOR THE PROTECTION AGAINST HONEYBEE MITES, AND METHOD FOR THE PREPARATION OF THE ACTIVE SUBSTANCE | VON BARTHELDNE ABRI JUDIT (HU) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | CYP1A2 849/4885ADRA2A 4426/4885ALDH1A1 1472/4885 |
| US-12569679-B2 | Treatment delivery system | PIEZO1, DSG1, KRT18 | CYP1A2 2615/4885ADRA2A 1090/4885ALDH1A1 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.